8th EUFEPS Talks
We want to invite you to the 8th EUFEPS Talks on September 12, 2022 at 4 pm CEST.
Prof. Maria José Alonso (CIMUS Research Institute, Santiago de Compostela, Spain) will give a talk with the title: "Pharmaceutical Nanotechnology enables Biological Drugs to reach their Targets". Here you could download the CV of Prof. Alonso.
A registration is needed for this event. Please use the following link: https://us06web.zoom.us/meeting/register/tZYkf-mvrT0qGdLSgmgd1Ga1qHgZaP9E2euf. After the regristration you will receive an E-Mail with the log-in details.
Biological drugs, including proteins and RNA-based polynucleotides, are taking an increasing space in the industry pipelines. Despite their potency, the adequate exploitation of these macromolecules has been restrained by their difficulties for overcoming biological barriers and reach the intracellular targets.
Fortunately, the continuously improved understanding of the biological barriers and the molecular biology associated to pathological conditions is paving the way for a more comprehensive and rational design of protein formulations based on the use of nanotechnology. Our laboratory, with a long-track experience in the formulation of biological drugs using biomaterials, has significantly contributed to this field. As an example, in the 90’s we were the first to report that nanoparticles made of biopolymers and/or lipids were efficient vehicles for the transmucosal delivery of proteins, antigens and polynucleotides. In the last decades, we have made significant advances in terms of enabling the intracellular delivery of monoclonal antibodies and RNA molecules. The result of our subsequent efforts is an array of nanotechnologies, which can be used to to develop advanced therapies and vaccines as well as personalized treatments.
In my presentation, I will focus on the design of carriers for proteins and RNA molecules that could be used in two major therapeutic areas: (i) nanovaccines, i.e. HIV and COVID vaccines (ii) oncological personalized therapies based mAb and siRNA targeted to intracellular onco-proteins.
Overall, our experience in this field has benefited from integrative approaches adopted by specifically designed consortia. Hopefully, the results of these cooperative efforts will help to accelerate the progress of a rational design of protein-based nanomedicines.
More information about these projects and associated publications can be found at: http://www.usc.es/grupos/mjalonsolab/
The following researchers have contributed to different projects:
Anticancer drug delivery: Desirée Teijeiro, Shubaash Anthiya, Spain.
Vaccine delivery: Mireya Borrajo, Shubaash Anthiya, Jose Crecente, Tamara Gómez from the USC and Ma Luo from University of Manitoba, Canada.
The research activity has been founded by The National Institutes of Health (NIH) (Grant Number: R01AI11180; MINECO- PCIN-2017-129/ AEI, SARS-CoV2”, Instituto Salud Carlos III, FEDER Funds, Ref. COV20/00214; AES 2020, Award N. AC20/00028 and within the framework of EuroNanoMed III. FEDER/Ministerio de Ciencia, Innovación y Universidades – AEI/ Proyecto- PID2020-119368RB-I00; Competitive Reference Groups, Consellería de Educación e Ordenación Universitaria, Xunta de Galicia, Ref: ED431C 2021/17.